The main pharmacological target for Alzheimer’s disease (AD) treatment is acetylcholinesterase (AChE), a biochemical enzyme belonging to the cholinesterase (ChE) family. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.